Pharma: Other News To Note

• Novo Nordisk A/S, of Bagsvaerd, Denmark, said the Japanese Ministry of Health, Labour and Welfare approved Tresiba (insulin degludec) to treat diabetes. The once-daily basal insulin studies showed a duration of action lasting beyond 42 hours in trials including 10,000 patients with Type I or Type II diabetes.